NCT07447570 2026-03-03
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
Akeso
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
UNICANCER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's